[go: up one dir, main page]

GB201715122D0 - Topical anti-infective formulation - Google Patents

Topical anti-infective formulation

Info

Publication number
GB201715122D0
GB201715122D0 GBGB1715122.6A GB201715122A GB201715122D0 GB 201715122 D0 GB201715122 D0 GB 201715122D0 GB 201715122 A GB201715122 A GB 201715122A GB 201715122 D0 GB201715122 D0 GB 201715122D0
Authority
GB
United Kingdom
Prior art keywords
topical anti
infective formulation
infective
formulation
topical
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB1715122.6A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Omnipharm Dev Ltd
Original Assignee
Omnipharm Dev Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Omnipharm Dev Ltd filed Critical Omnipharm Dev Ltd
Priority to GBGB1715122.6A priority Critical patent/GB201715122D0/en
Publication of GB201715122D0 publication Critical patent/GB201715122D0/en
Priority to PCT/IB2018/057203 priority patent/WO2019058268A1/en
Ceased legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/60Salicylic acid; Derivatives thereof
    • A61K31/609Amides, e.g. salicylamide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0014Skin, i.e. galenical aspects of topical compositions
    • A61K9/0017Non-human animal skin, e.g. pour-on, spot-on
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Zoology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
GBGB1715122.6A 2017-09-19 2017-09-19 Topical anti-infective formulation Ceased GB201715122D0 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
GBGB1715122.6A GB201715122D0 (en) 2017-09-19 2017-09-19 Topical anti-infective formulation
PCT/IB2018/057203 WO2019058268A1 (en) 2017-09-19 2018-09-19 Topical anti-infective formulation

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1715122.6A GB201715122D0 (en) 2017-09-19 2017-09-19 Topical anti-infective formulation

Publications (1)

Publication Number Publication Date
GB201715122D0 true GB201715122D0 (en) 2017-11-01

Family

ID=60159303

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB1715122.6A Ceased GB201715122D0 (en) 2017-09-19 2017-09-19 Topical anti-infective formulation

Country Status (2)

Country Link
GB (1) GB201715122D0 (en)
WO (1) WO2019058268A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11318149B2 (en) * 2018-09-27 2022-05-03 Board Of Trustees Of Michigan State University Compositions and methods for inhibiting biofilm-forming bacteria
CN111214449B (en) * 2020-03-02 2021-09-07 广东彼迪药业有限公司 A kind of cetirizine hydrochloride tablet and preparation method thereof
JP2024546893A (en) * 2021-12-17 2024-12-26 ビーエーエスエフ ソシエタス・ヨーロピア Compositions Comprising Antimicrobial Agents and Carboxamides

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI260220B (en) * 1999-11-22 2006-08-21 Novartis Ag A pharmaceutical composition for the transdermal treatment of bacterial infections in animals
GB0316377D0 (en) * 2003-07-12 2003-08-13 Norbrook Lab Ltd Parasiticidal composition
US7576054B2 (en) * 2005-10-11 2009-08-18 Biosynexus Incorporated Compositions and methods for treating bacteria
WO2012023082A1 (en) * 2010-08-17 2012-02-23 Sulur Subramaniam Vanangamudi A medicinal fusidic acid cream made using sodium fusidate and incorporating a biopolymer, a corticosteroid - hydrocortisone acetate, and an antifungal agent - terbinafine hydrochloride, and a process to make it
FR2991173B1 (en) * 2012-06-04 2015-11-06 Virbac VETERINARY COMPOSITION WITH OXYCLOZANIDE BASED SKIN ADMINISTRATION

Also Published As

Publication number Publication date
WO2019058268A1 (en) 2019-03-28

Similar Documents

Publication Publication Date Title
ZA202007965B (en) Topical pharmaceutical compositions
SG11201701292XA (en) Topical formulation
ZA201800080B (en) Topical retinoid compositions
GB201604484D0 (en) Topical antibacterial compositions
IL274139A (en) Aerosolisable formulation
GB201709918D0 (en) Topical formulation
SG11202000615VA (en) Topical composition
IL274719A (en) Formulation
GB201514758D0 (en) Formulation
GB201713724D0 (en) Formulation
PT3173071T (en) Maropitant formulation
GB201502845D0 (en) Topical pharmaceutical formulation
IL272944A (en) Topical compositions
IL268374A (en) Topical composition
GB201715122D0 (en) Topical anti-infective formulation
GB201706969D0 (en) Formulation
GB201719464D0 (en) Formulation
GB201713160D0 (en) Topical composition
ZA201605935B (en) Topical antibiotic formulations
GB201521771D0 (en) Formulation
GB201511255D0 (en) Formulation
GB201509891D0 (en) Formulation
GB201609968D0 (en) Topical pharmaceutical formulation
EP3322482C0 (en) Topical ciprofloxacin compositions
GB201513108D0 (en) Topical composition

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)